Clinical trials: Cerebellum
Ataxia Telangiectasia
Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects
A Randomized, Open-label, Crossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 Administered as an Oral Spray Compared to Intramuscular Injection - betamethasone and an Oral Solution…
- Trial name
- NCT05531890
- Testing
- GTX-102 medium dose fast Period 1 and Period 2, GTX-102 medium dose slow Period 1 and Period 2, GTX-102 high dose fast Period 1 and Period 2
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Grace Therapeutics Inc.
Friedreich Ataxia, Cardiomyopathies
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults
The goal of this clinical trial is to learn how ATI-105 administered to healthy participants at works in the body at different doses and with or without food.
- Conditions
- Friedreich Ataxia, Cardiomyopathies, Central Nervous System Diseases, Neuromuscular Diseases
- Trial name
- NCT07869654
- Testing
- ATI-105
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Adjuvia Therapeutics, Inc.
Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00994500
- Testing
- vorinostat, bortezomib, pharmacological study
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
In the laboratory, Kevetrin activates p53, a tumor suppressor protein that has an important role in protecting the body. p53 functions by activating proteins that repair DNA and kill cells that have genetic mutations such as in…
- Trial name
- NCT01664000
- Testing
- thioureidobutyronitrile
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Cellceutix Corporation
Friedreich Ataxia
Measurement of Frataxin mRNA in Biofluids
The purpose of this research study is to determine a way to measure frataxin messenger RNA (mRNA) in fluids such as blood and cerebrospinal fluid (CSF) from patients with Friedreich's ataxia (FRDA).
- Trial name
- NCT06496451
- Testing
- Spinal tap for CSF collection, Venipuncture for blood sample
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Colorectal Neoplasms
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
- Trial name
- NCT03631407
- Testing
- Vicriviroc, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Cerebellar Ataxia, Neuropathy
Evaluation of Urinary Dysfunction in CANVAS Patients
The investigator wishes to evaluate the prevalence of urinary symptoms in patients diagnosed with Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS).
- Conditions
- Cerebellar Ataxia, Neuropathy, Vestibular Areflexia
- Trial name
- UROCANVAS (NCT06817707)
- Testing
- Evaluation of urinary dysfunction in patients with CANVAS
- Where
- 3 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Cerebellar Function, Transcranial Magnetic Stimulation
Enhanced Recovery After Surgery Using TMS on Cerebellar Language Area for Brain Tumor Patients
At present, the incidence of language dysfunction in patients with brain language area tumor in the first month after operation was 20%-40%.
- Conditions
- Cerebellar Function, Transcranial Magnetic Stimulation, Language Disorders
- Trial name
- NCT03974659
- Testing
- Transcranial magnetic stimulation
- Where
- 2 sites in China
- Volunteers
- 106 people
- Sponsor
- Huashan Hospital
Transcranial Electrical Stimulation, Temporal Lobe Epilepsy
Transcranial Electrical Stimulation Targeting the Cerebellum for the Treatment of Refractory Temporal Lobe Epilepsy
Study the therapeutic effect and potential neural mechanisms of transcranial electrical stimulation targeting the cerebellum for the treatment of refractory temporal lobe epilepsy through MRI and EEG.
- Conditions
- Transcranial Electrical Stimulation, Temporal Lobe Epilepsy, Magnetic Resonance Imaging, Electroencephalogram
- Trial name
- NCT06558890
- Testing
- Transcranial Alternating Current Stimulation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital
Friedreich's Ataxia
An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia
The purpose of this study is to learn how treatment with acetyl-L-carnitine (ALCAR) will affect the hearts of patients with Friedreich's Ataxia as well as how it may affect other symptoms of Friedreich's Ataxia such as…
- Trial name
- NCT01921868
- Testing
- Acetyl-L-Carnitine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of South Florida
Myoclonus-Dystonia, DYT11
EMOTION & COGNITION IN MYOCLONUS DYSTONIA (AGENT10-ECODYST)
Background: Myoclonus dystonia (DYT-SGCE) is characterized by myoclonus and dystonia. Such condition is associated with a high prevalence of psychiatric symptoms which are part of the phenotype.
- Trial name
- NCT05671068
- Where
- France
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Ataxia, Cerebellar
tDCS Associated With Locomotor Training on Functional Mobility of Cerebellar Ataxia
Cerebellar ataxia is a neurologic symptom caused by a damage or a dysfunction in cerebellum and results in loss of coordination, balance and postural control.
- Trial name
- NCT03703830
- Testing
- Cerebellar transcranial direct current stimulation, Treadmill locomotor training, Cerebello-spinal direct current stimulation
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Universidade Federal de Pernambuco
Methamphetamine Use Disorder
Cerebellum-Prefrontal Paired-Pulse Stimulation for Methamphetamine Use Disorder
To investigate the mechanism and efficacy of a novel repetitive transcranial magnetic stimulation (rTMS) intervention model with paired cerebellar-medial prefrontal cortex (mPFC) pulses on methamphetamine use disorder patients…
- Trial name
- NCT06457230
- Testing
- Paired Associative Stimulation Targeting the Cerebellar-mPFC
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Friedreich Ataxia
NAD+ Precursor Supplementation in Friedreich's Ataxia
The primary objective is to test the safety and tolerability of short-term therapy with a nicotinamide adenine dinucleotide (NAD+) precursor (MIB-626) in adults with Friedreich's Ataxia (FA) without overt heart failure and with a…
- Trial name
- NCT04817111
- Testing
- MIB-626
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Metro International Biotech, LLC
Brain and Central Nervous System Tumors
Lobradimil and Carboplatin in Treating Children With Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Lobradimil may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the…
- Trial name
- NCT00019422
- Testing
- carboplatin, lobradimil
- Where
- 236 sites in United States, Australia and 5 more
- Sponsor
- National Cancer Institute (NCI)
Cerebellum; Injury
Neurorehabilitation Impact on Neurocognitive Impairments in Cerebellar Lesions
Depending on their localization, cerebellar lesions cause various pronounced cognitive and/or affective dysfunctions, which are causally related to the involvement of cerebellar structures in neuronal networks for higher-order…
- Trial name
- NRCEcog (NCT05529745)
- Testing
- Neurorehabilitation cerebellar cognitive disorder
- Volunteers
- 50 people
- Sponsor
- Klinik Bavaria
Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 3
Cerebellar DBS in SCA1 and SCA3 Study
The purpose of this study is to evaluate the safety and feasibility of deep brain stimulation (DBS) in the deep cerebellar nuclei (DCN) in patients with Spinocerebellar Ataxia (SCA) types 1 and 3.
- Trial name
- NCT07752095
- Testing
- UG3NS140720 Deep Brain Stimulation System
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Gordon H. Baltuch
Ataxia, Cerebellar, Ataxia, Progressive
Effect of Nilotinib in Cerebellar Ataxia Patients
This is an institutional cohort study. Patients confirmed with spinocerebellar ataxia (SCA) and taking or planning to take Nilotinib (Tasigna®) are enrolled in this study.
- Trial name
- NCT03932669
- Testing
- Nilotinib
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Seoul National University Hospital
Pulp Inflammation
Analysis of the Influence of Desensitizing Treatments on the Pulp Inflammatory Response in Bleached Teeth
This randomized, controlled, blinded clinical trial evaluated the effectiveness of different desensitizing protocols in preventing pulp inflammation after bleaching treatment with 35% hydrogen peroxide (PH) (Whiteness PH 35%).
- Trial name
- NCT04548674
- Testing
- Whiteness HP 35%, Whiteness HP 35% + LASER, Whiteness HP 35% + CPP
- Where
- Brazil
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Para
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00020150
- Testing
- O6-benzylguanine, temozolomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)